WEBULL

Diagnostic Medical Systems S.A. (EPA:ALDMS) Is About To Turn The Corner

Simply Wall St · 1d ago

We feel now is a pretty good time to analyse Diagnostic Medical Systems S.A.'s (EPA:ALDMS) business as it appears the company may be on the cusp of a considerable accomplishment. Diagnostic Medical Systems S.A. designs, develops, manufactures, and sells medical imaging systems in France. The €27m market-cap company announced a latest loss of €167k on 31 December 2025 for its most recent financial year result. As path to profitability is the topic on Diagnostic Medical Systems' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Diagnostic Medical Systems is bordering on breakeven, according to some French Medical Equipment analysts. They expect the company to post a final loss in 2025, before turning a profit of €800k in 2026. The company is therefore projected to breakeven around a year from now or less! At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 72%, which signals high confidence from analysts. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

earnings-per-share-growth
ENXTPA:ALDMS Earnings Per Share Growth July 25th 2026

We're not going to go through company-specific developments for Diagnostic Medical Systems given that this is a high-level summary, though, bear in mind that typically a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

See our latest analysis for Diagnostic Medical Systems

One thing we would like to bring into light with Diagnostic Medical Systems is its relatively high level of debt. Typically, debt shouldn’t exceed 40% of your equity, which in Diagnostic Medical Systems' case is 72%. Note that a higher debt obligation increases the risk in investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on Diagnostic Medical Systems, so if you are interested in understanding the company at a deeper level, take a look at Diagnostic Medical Systems' company page on Simply Wall St. We've also put together a list of key factors you should further research:

  1. Valuation: What is Diagnostic Medical Systems worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Diagnostic Medical Systems is currently mispriced by the market.
  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Diagnostic Medical Systems’s board and the CEO’s background.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.